




# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER  
PARTNER  
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184  
TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

March 16, 2004

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Box Sequence, Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202, on the date below:	
March 16, 2004	
Date	Steven L. Highlander

**MS DD**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Re: *U.S. Patent Application No. 10/752,380 entitled, "EBV CTL EPITOPES" by Rajiv Khanna et al.*  
*Our Ref. No. FBRC:008USC3*  
*Client Ref. No. 502023/MRO*


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement and Form PTO-1449.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/FBRC:08USC3.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

  
Steven L. Highlander  
Reg. No. 37,642

SLH/cas  
Encl.: as noted



**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Rajiv Khanna et al.

Serial No.: 10/752,380.


Filed: January 6, 2004

For: EBV CTL EPITOPES

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: FBRC:008USC3

<b>CERTIFICATE OF MAILING</b> 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.	
March 16, 2004	
Date	Steven L. Highlander

**INFORMATION DISCLOSURE STATEMENT**

**MS DD**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/FBRC:008USC3.

This application is a continuation application of Serial No. 09/194,450, filed June 25, 1999 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) copies of the listed documents are not enclosed as they have been previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 09/194,450.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: March 16, 2004

**Form PTO-1449** (modified)

List of Patents and Publications for Applicant's

**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Atty. Docket No.

FBRC:008USC3

Serial No.

10/752,380

Applicants

Rajiv Khanna *et al.*

Filing Date:

January 6, 2004

Group:

Unknown

U.S. Patent Documents

*See Page 1*

Foreign Patent Documents

*See Page 1*

Other Art

*See Page 1***U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date if App.

**Foreign Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 95/24925	9/21/95	PCT			

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C1	Addinger <i>et al.</i> , "A putative transforming gene of Jijoye virus differs from that of Epstein-Barr virus prototypes," <i>Virology</i> , 141:221-234, 1985.
	C2	Andrew <i>et al.</i> , "The roles of influenza virus haemagglutinin and nucleoprotein in protection: analysis using vaccinia virus recombinants," <i>Scand. J. Immunol.</i> , 25:21-28, 1987.
	C3	Apolloni <i>et al.</i> , "Sequence variation of cytotoxic T cell epitopes in different isolates of Epstein-Barr virus," <i>European Journal of Immunology</i> , 22:183-189, 1992.
	C4	Apolloni and Sculley, "Detection of A-type and B-type Epstein-Barr virus in throat washings and lymphocytes," <i>Virology</i> , 202:978-981, 1994.
	C5	Bogedain <i>et al.</i> , "Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus," <i>J. Virol.</i> , 69:4872-4879, 1995.
	C6	Brooks <i>et al.</i> , "Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide," <i>J. Exp. Med.</i> , 178:879-887, 1993.
	C7	Buisson <i>et al.</i> , "Changes in the dominant Epstein-Barr virus type during human immunodeficiency virus infection," <i>J. Gen. Virol.</i> , 75:431-437, 1994.
	C8	Burrows <i>et al.</i> , "An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants," <i>Journal of Virology</i> , 64(8):3974-3976, 1990.
	C9	Burrows <i>et al.</i> , "Bystander apoptosis induced by CD8+ cytotoxic T cell (CTL) clones: implications for CTL lytic mechanisms," <i>Int. Immunol.</i> , 5:1049-1058, 1993.

25381873.1

**Examiner:****Date Considered:**

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>Form PTO-1449</b> (modified)		Atty. Docket No. FBRC:008USC3	Serial No. 10/752,380
List of Patents and Publications for Applicant's  <b>INFORMATION DISCLOSURE STATEMENT</b>  (Use several sheets if necessary)		Applicants Rajiv Khanna <i>et al.</i>	
		Filing Date: January 6, 2004	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C10	Burrows <i>et al.</i> , "The specificity of recognition of a cytotoxic T lymphocyte epitope," <i>Eur. J. Immunol.</i> , 22:191-195, 1992.
	C11	Burrows <i>et al.</i> , "Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3," <i>J. Gen. Virol.</i> , 75:2489-2493, 1994.
	C12	Crawford <i>et al.</i> , "Epstein-Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft," <i>Lancet</i> , 1:1355-1356, 1980.
	C13	Dambaugh <i>et al.</i> , "U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2," <i>Proc. Natl. Acad. Sci. USA</i> , 81:7632-7636, 1984.
	C14	Doherty <i>et al.</i> , "Evasion of host immune responses by tumours and viruses," <i>Ciba. Found. Symp.</i> , 187:245-260, 1994.
	C15	Fazekas de St. Groth, "The evaluation of limiting dilution assays," <i>J. Immunol. Methods</i> , 49:R11-23, 1982.
	C16	Gavioli <i>et al.</i> , "Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4," <i>J. Virol.</i> , 67:1572-1578, 1993.
	C17	Gratama <i>et al.</i> , "Detection of multiple 'Ebnotypes' in individual Epstein-Barr virus carriers following lymphocyte transformation by virus derived from peripheral blood and oropharynx," <i>J. Gen. Virol.</i> , 75:85-94, 1994.
	C18	Gregory <i>et al.</i> , "Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line," <i>J. Gen. Virol.</i> , 71:1481-1495, 1990.
	C19	Henle <i>et al.</i> , "Rheumatoid factor as a cause of positive reactions in tests for Epstein-Barr virus-specific IgM antibodies," <i>Clin. Exp. Immunol.</i> , 36:415-422, 1979.
	C20	Henle and Henle, "Seroepidemiology of the virus," In: <i>The Epstein-Barr Virus</i> , Epstein and Achong (eds.), 61-78, 1979.
	C21	Hill <i>et al.</i> , "Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7," <i>Eur. J. Immunol.</i> , 25:18-24, 1995.
	C22	Hill <i>et al.</i> , "Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV) nuclear antigens fail to lyse the EBV-transformed B lymphoblastoid cell lines against which they were raised," <i>J. Exp. Med.</i> , 181:2221-2228, 1995.

25381873.1

<b>Examiner:</b>	<b>Date Considered:</b>
EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>Form PTO-1449</b> (modified)		Atty. Docket No. FBRC:008USC3	Serial No. 10/752,380
List of Patents and Publications for Applicant's  <b>INFORMATION DISCLOSURE STATEMENT</b>  (Use several sheets if necessary)		Applicants Rajiv Khanna <i>et al.</i>	
		Filing Date: January 6, 2004	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C23	Fu <i>et al.</i> , "Variable expression of latent membrane protein in nasopharyngeal carcinoma can be related to methylation status of the Epstein-Barr virus BNLF-1 5'-flanking region," <i>J. Virol.</i> , 65:1558-1567, 1991.
	C24	Kerdiles <i>et al.</i> , "cDNA cloning and transient expression of the Epstein-Barr virus-determined nuclear antigen EBNA3B in human cells and identification of novel transcripts from its coding region," <i>J. Virol.</i> , 64:1812-1816, 1990.
	C25	Kerr <i>et al.</i> , "Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus," <i>Journal of Virology</i> , 70(12):8858-8864, 1996.
	C26	Khanna <i>et al.</i> , "Localization of Epstein-Barr virus cytotoxic T-cell epitopes using recombinant vaccinia: implications for vaccine development," <i>J. Exp. Med.</i> , 176:169-176, 1992.
	C27	Khanna <i>et al.</i> , "Immune regulation in Epstein-Barr virus-associated diseases," <i>Microbiol. Rev.</i> , 59:387-405, 1995.
	C28	Khanna <i>et al.</i> , "Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T-cells," <i>Immunology</i> , 74:504-510, 1991.
	C29	Khanna <i>et al.</i> , "Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance," <i>Virology</i> , 214:633-637, 1995).
	C30	Kyaw <i>et al.</i> , "Expression of B-type Epstein-Barr virus in HIV-infected patients and cardiac transplant recipients," <i>AIDS Res. Hum. Retroviruses</i> , 8:1869-1874, 1992.
	C31	Landau <i>et al.</i> , "Presence of infective Epstein-Barr virus in the urine of patients with infectious mononucleosis," <i>J. Med. Virol.</i> , 44:229-233, 1994.
	C32	Laroche <i>et al.</i> , "Measurement by the polymerase chain reaction of the Epstein-Barr virus load in infectious mononucleosis and AIDS-related non-Hodgkin's lymphomas," <i>J. Med. Virol.</i> , 46:66-74, 1995.
	C33	Lear <i>et al.</i> , "The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle," <i>J. Virol.</i> , 66:7461-7468, 1992.
	C34	Lee <i>et al.</i> , "HLA A2.1 restricted cytotoxic T-cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2," <i>J. Virol.</i> , 67:7428-7435, 1993.

25381873.1

Examiner:

Date Considered:

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>Form PTO-1449</b> (modified)		Atty. Docket No. FBRC:008USC3	Serial No. 10/752,380
List of Patents and Publications for Applicant's  <b>INFORMATION DISCLOSURE STATEMENT</b>  (Use several sheets if necessary)		Applicants Rajiv Khanna <i>et al.</i>	
		Filing Date: January 6, 2004	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C35	Lewin <i>et al.</i> , "Characterization of EBV-carrying B-cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth," <i>Int. J. Cancer</i> , 39:472-476, 1987.
	C36	Lung <i>et al.</i> , "Epstein-Barr virus genotypes associated with nasopharyngeal carcinoma in southern China," <i>Virology</i> , 177:44-53, 1990.
	C37	Miller <i>et al.</i> , "An integral membrane protein (Imp2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking," <i>Proc. Natl. Acad. Sci. USA</i> , 91:772-776, 1994.
	C38	Miller and Hutt-Fletcher, "A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus," <i>J. Virol.</i> , 62:2366-2372, 1988.
	C39	Misko <i>et al.</i> , "Factors influencing the human cytotoxic T-cell response to autologous lymphoblastoid cell lines <i>in vitro</i> ," <i>Clin. Immunol. Immunopathol.</i> , 32:285-297, 1984.
	C40	Miyashita <i>et al.</i> , "A novel form of Epstein-Barr virus latency in normal B cells <i>in vivo</i> ," <i>Cell</i> , 80:593-601, 1995.
	C41	Morgan <i>et al.</i> , "A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory <i>in vitro</i> ," <i>J. Virol.</i> , 70:2394-2402, 1996.
	C42	Moss <i>et al.</i> , "Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants," <i>Nature</i> , 331:719-721, 1988.
	C43	Moss <i>et al.</i> , "Long-term T-cell-mediated immunity to Epstein-Barr virus in man. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes," <i>Int. J. Cancer</i> , 22:662-668, 1978.
	C44	Murray <i>et al.</i> , "Identification of target antigens for the human cytotoxic T-cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies," <i>J. Exp. Med.</i> , 176:157-168, 1992.
	C45	Murray <i>et al.</i> , "Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses," <i>Proc. Natl. Acad. Sci. USA</i> , 87:2906-2910, 1990.
	C46	Nilsson <i>et al.</i> , "The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV," <i>Int. J. Cancer</i> , 8:443-450, 1991.

25381873.1

Examiner:

Date Considered:

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>Form PTO-1449</b> (modified)		Atty. Docket No. FBRC:008USC3	Serial No. 10/752,380
List of Patents and Publications for Applicant's  <b>INFORMATION DISCLOSURE STATEMENT</b>  (Use several sheets if necessary)		Applicants Rajiv Khanna <i>et al.</i>	
		Filing Date: January 6, 2004	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C47	Okano <i>et al.</i> , "Severe chronic active Epstein-Barr virus infection syndrome," <i>Clin. Microbiol. Rev.</i> , 4:129-135, 1991.
	C48	Polack <i>et al.</i> , "A complete set of overlapping cosmid clones of M-ABA virus derived from nasopharyngeal carcinoma and its similarity to other Epstein-Barr virus isolates," <i>Gene</i> , 27:279-288, 1984.
	C49	Pope <i>et al.</i> , "Burkitt lymphoma in New Guinea: establishment of a line of lymphoblasts <i>in vitro</i> and description of their fine structure," <i>J. Natl. Cancer Inst.</i> , 39:933-945, 1967.
	C50	Pope <i>et al.</i> , "Transformation of foetal human leucocytes <i>in vitro</i> by filtrates of a human leukaemic cell line containing herpes-like virus," <i>Int. J. Cancer</i> , 3:857-865, 1968.
	C51	Rammensee <i>et al.</i> , "MHC ligands and peptide motifs: first listing," <i>Immunogenetics</i> , 41:178-228, 1995.
	C52	Ressing <i>et al.</i> , "Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through <i>in vivo</i> and <i>in vitro</i> immunogenicity studies of HLA-A 0201-binding peptides," <i>J. Immunol.</i> , 154:5934-5943, 1995.
	C53	Rickinson <i>et al.</i> , "T-cell mediated regression of spontaneous and of Epstein-Barr virus-induced B-cell transformation <i>in vitro</i> : studies with cyclosporin A," <i>Cell. Immunol.</i> , 87:646-658, 1984.
	C54	Rickinson <i>et al.</i> , "Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells," <i>J. Virol.</i> , 61:1310-1317, 1987.
	C55	Rooney <i>et al.</i> , "Paired Epstein-Barr virus-carrying lymphoma and lymphoblastoid cell lines from Burkitt's lymphoma patients: comparative sensitivity to non-specific and to allo-specific cytotoxic responses <i>in vitro</i> ," <i>Int. J. Cancer</i> , 34:339-348, 1984.
	C56	Rooney <i>et al.</i> , "Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance," <i>Nature</i> , 317:629-631, 1985.
	C57	Rosenberg <i>et al.</i> , "Biological activity of recombinant human interleukin-2 produced in <i>E. coli</i> ," <i>Science</i> , 223:1412-1414, 1984.
	C58	Sample and Kieff, "Transcription of the Epstein-Barr virus genome during latency in growth-transformed lymphocytes," <i>J. Virol.</i> , 64:1667-1674, 1990.

25381873.1

Examiner:

Date Considered:

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>Form PTO-1449</b> (modified)		Atty. Docket No. FBRC:008USC3	Serial No. 10/752,380
List of Patents and Publications for Applicant's  <b>INFORMATION DISCLOSURE STATEMENT</b>  (Use several sheets if necessary)		Applicants Rajiv Khanna <i>et al.</i>	
		Filing Date: January 6, 2004	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C59	Schmidt <i>et al.</i> , "Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies," <i>Proc. Natl. Acad. Sci. USA</i> , 88:9478-9482, 1991.
	C60	Sculley <i>et al.</i> , "Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects," <i>J. Infect. Dis.</i> , 162:643-648, 1990.
	C61	Sculley <i>et al.</i> , "Expression of Epstein-Barr virus nuclear antigens 3, 4 and 6 are altered in cell lines containing B-type virus," <i>Virology</i> , 171:401-408, 1989.
	C62	Selin <i>et al.</i> , "Cross-reactivities in memory cytotoxic T lymphocyte recognition of heterologous viruses," <i>J. Exp. Med.</i> , 179:1933-1943, 1994.
	C63	Sixbey <i>et al.</i> , "Detection of a second widespread strain of Epstein-Barr virus," <i>Lancet</i> , 2:761-765, 1989.
	C64	Silins <i>et al.</i> , "Isolation of Epstein-Barr virus genomes using pulse-field gel electrophoresis," <i>Nucleic Acids Res.</i> , 20:2901, 1992.
	C65	Sumaya and Ench, "Epstein-Barr virus infectious mononucleosis in children. Clinical and general laboratory findings," <i>Pediatrics</i> , 75:1003-1010, 1985.
	C66	Sumaya and Ench, "Epstein-Barr virus infectious mononucleosis in children. Heterophil antibody and viral-specific responses," <i>Pediatrics</i> , 75(6):1011-1019, 1985.
	C67	Tomkinson <i>et al.</i> , "Activated lymphocytes during acute Epstein-Barr virus infection," <i>J. Immunol.</i> , 139:3802-3807, 1987.
	C68	Tussey <i>et al.</i> , "Different MHC class I alleles compete for presentation of overlapping viral epitopes," <i>Immunity</i> , 3:65-77, 1995.
	C69	Wagner <i>et al.</i> , "Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction," <i>J. Clin. Microbiol.</i> , 30:2826-2829, 1992.

25381873.1

Examiner:

Date Considered:

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.